Tag Archives: Voyager Therapeutics
Robert W. Baird Sticks to Their Buy Rating for Voyager Therapeutics (VYGR)
In a report issued on February 2, Brian Skorney from Robert W. Baird maintained a Buy rating on Voyager Therapeutics (VYGR – Research Report), with a price target of $18.00. The company’s shares closed last Friday at $5.67, close to
Voyager Therapeutics (VYGR) Receives a Buy from Canaccord Genuity
In a report issued on December 22, Sumant Kulkarni from Canaccord Genuity maintained a Buy rating on Voyager Therapeutics (VYGR – Research Report), with a price target of $14.00. The company’s shares closed last Tuesday at $8.69. According to TipRanks.com,
Wedbush Maintains Their Buy Rating on Voyager Therapeutics (VYGR)
In a report issued on August 11, Laura Chico from Wedbush maintained a Buy rating on Voyager Therapeutics (VYGR – Research Report), with a price target of $24.00. The company’s shares closed last Wednesday at $11.19. According to TipRanks.com, Chico
Nomura Maintains Their Buy Rating on Voyager Therapeutics (VYGR)
In a report issued on May 11, Christopher Marai from Nomura maintained a Buy rating on Voyager Therapeutics (VYGR – Research Report), with a price target of $16.00. The company’s shares closed last Wednesday at $11.37. According to TipRanks.com, Marai
Voyager Therapeutics (VYGR) Receives a Hold from Chardan Capital
Chardan Capital analyst Gbola Amusa reiterated a Hold rating on Voyager Therapeutics (VYGR – Research Report) on May 6 and set a price target of $15.00. The company’s shares closed last Friday at $11.15. According to TipRanks.com, Amusa is a
Oppenheimer Initiates a Buy Rating on Voyager Therapeutics (VYGR)
In a report released today, Jay Olson from Oppenheimer initiated coverage with a Buy rating on Voyager Therapeutics (VYGR – Research Report) and a price target of $26.00. The company’s shares closed last Monday at $12.62, close to its 52-week
